GEICAM Study: The Role of Xeloda in Treating Early-Stage Triple Negative Breast Cancer

Live from the 2018 San Antonio Breast Cancer Symposium, Breastcancer.org Chief Medical Officer Dr. Marisa Weiss discusses the results of the GEICAM study, which showed that patients with a certain type of triple-negative breast cancer (called “non-basal”) may benefit from extended treatment with Xeloda (capecitabine).

[@irenedavo3768]

Please watch videos of Jim Nduruchi called Rose with stage four breast cancer